ATC code J
Pharmaceutical drug classification
ATC code J: Antiinfectives for systemic use |
---|
|
Human only |
ATCvet only |
|
Other ATC codes |
ATC code J Antiinfectives for systemic use is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3][4]
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QJ.[5] ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
See also
- Immune sera, immunoglobulins and vaccines for veterinary use are in the ATCvet group QI.
References
- ^ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
- ^ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
- ^ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
- ^ "ATC/DDD Index 2022: code J". WHO Collaborating Centre for Drug Statistics Methodology.
- ^ "ATCvet Index 2022: code QJ". WHO Collaborating Centre for Drug Statistics Methodology.
Major chemical drug groups – based upon the Anatomical Therapeutic Chemical Classification System | |
---|---|
gastrointestinal tract / metabolism (A) | |
blood and blood forming organs (B) | |
cardiovascular system (C) | |
skin (D) | |
genitourinary system (G) | |
endocrine system (H) | |
infections and infestations (J, P, QI) | |
malignant disease (L01–L02) | |
immune disease (L03–L04) | |
muscles, bones, and joints (M) | |
brain and nervous system (N) |
|
respiratory system (R) | |
sensory organs (S) | |
other ATC (V) | |
30S |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
50S | |||||||||||||||
|
β-lactams (inhibit synthesis of peptidoglycan layer of bacterial cell wall by binding to and inhibiting PBPs, a group of D-alanyl-D-alanine transpeptidases) |
| ||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Polypeptides |
| ||||||||||||||||||||||||||||||||||||||||||
Intracellular |
| ||||||||||||||||||||||||||||||||||||||||||
Other |
| ||||||||||||||||||||||||||||||||||||||||||
|
Antifolates (inhibit bacterial purine metabolism, thereby inhibiting DNA and RNA synthesis) |
| ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Quinolones (inhibit bacterial topoisomerase and/or DNA gyrase, thereby inhibiting DNA replication) |
| ||||||||||||||||
Anaerobic DNA inhibitors |
| ||||||||||||||||
RNA synthesis |
| ||||||||||||||||
|
Glycopeptides Lipoglycopeptides | |
---|---|
Polymyxins | |
Steroid antibacterials | |
Imidazole derivatives | |
Pleuromutilins | |
Nitrofuran derivatives | |
Other antibacterials |
Wall/ membrane |
| ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intracellular |
| ||||||||||||||||||||||
Others |
| ||||||||||||||||||||||
|
Nucleic acid inhibitor |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Protein synthesis inhibitor |
| ||||||||
Cell envelope antibiotic |
| ||||||||
Other/unknown | |||||||||
Combinations | |||||||||
|
Baltimore I |
| ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hepatitis B (VII) | |||||||||||||||||||||
Multiple/general |
| ||||||||||||||||||||
|
Hepatitis C |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Hepatitis D | |||||||||
Picornavirus | |||||||||
Anti-influenza agents | |||||||||
Multiple/general |
| ||||||||
|
Capsid inhibitors | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Entry/fusion inhibitors (Discovery and development) | |||||||||||||
Integrase inhibitors (Integrase strand transfer inhibitors (INSTI)) | |||||||||||||
Maturation inhibitors | |||||||||||||
Protease Inhibitors (PI) (Discovery and development) |
| ||||||||||||
Reverse-transcriptase inhibitors (RTIs) |
| ||||||||||||
Combined formulations |
| ||||||||||||
Pharmacokinetic boosters | |||||||||||||
Experimental agents |
| ||||||||||||
|
Immune sera and immunoglobulins (J06) | |||||
---|---|---|---|---|---|
Polyclonal antibodies |
| ||||
Monoclonal antibodies |
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|